Alam S M, Fujimoto J, Jahan I, Sato E, Tamaya T
Department of Obstetrics and Gynecology, Gifu University School of Medicine, Yanagido 1-1, Gifu City 501-1194, Japan.
Br J Cancer. 2008 Feb 26;98(4):845-51. doi: 10.1038/sj.bjc.6604216. Epub 2008 Jan 29.
EphB4 and ephrinB2 expressions in ovarian cancers were studied to analyse EphB4/ephrinB2 functions against clinical backgrounds. EphB4 and ephrinB2 were dominantly localised in ovarian cancer cells of all cases studied. Both the histoscores and mRNA levels of EphB4 and ephrinB2 significantly increased with clinical stages (I<II<III<IV, P<0.001) in ovarian cancers, although there was no significant difference in EphB4 and ephrinB2 histoscores or in mRNA levels according to histopathological types. EphB4 as well as ephrinB2 histoscores in cancer cells correlated with the corresponding mRNA levels in each case (EphB4, P<0.001; ephrinB2, P<0.001). The 24-month survival rates of the 36 patients with high EphB4 and ephrinB2 expression were poor (25 and 27%, respectively), while for the other 36 patients with low EphB4 and ephrinB2 expression, they were significantly higher (68 and 64%, respectively). Therefore, EphB4/ephrinB2 may function in tumour advancement and coexpression of the Eph/ephrin system may potentiate tumour progression leading to poor survival. Thus, EphB4/ephrinB2 can be recognised as a novel prognostic indicator in the primary tumours of ovarian cancers.
研究了EphB4和ephrinB2在卵巢癌中的表达，以分析EphB4/ephrinB2在临床背景下的功能。在所有研究病例的卵巢癌细胞中，EphB4和ephrinB2主要定位。在卵巢癌中，EphB4和ephrinB2的组织学评分和mRNA水平均随临床分期（I<II<III<IV，P<0.001）显著增加，尽管根据组织病理学类型，EphB4和ephrinB2的组织学评分或mRNA水平无显著差异。癌细胞中的EphB4以及ephrinB2组织学评分与每种情况下相应的mRNA水平相关（EphB4，P<0.001；ephrinB2，P<0.001）。36例EphB4和ephrinB2高表达患者的24个月生存率较差（分别为25%和27%），而其他36例EphB4和ephrinB2低表达患者的生存率显著更高（分别为68%和64%）。因此，EphB4/ephrinB2可能在肿瘤进展中起作用，Eph/ephrin系统的共表达可能促进肿瘤进展导致生存率低下。因此，EphB4/ephrinB2可被视为卵巢癌原发性肿瘤中的一种新型预后指标。
